Management of Hyperkalemia

Classification and Initial Evaluation

The American College of Cardiology recommends classifying hyperkalemia as mild (5.0-5.9 mEq/L), moderate (6.0-6.4 mEq/L), or severe (≥6.5 mEq/L), with urgent treatment indicated by the presence of electrocardiographic changes regardless of the absolute potassium level 1, 2
Before initiating treatment, it is critical to verify that the hyperkalemia is not pseudohyperkalemia due to hemolysis, repeated fist clenching, or inadequate phlebotomy technique by repeating the measurement with appropriate technique or arterial sample 1, 2
Obtain an electrocardiogram immediately to check for peaked T waves, flattened P waves, prolonged PR interval, and widened QRS complex 1, 2, 3

For severe hyperkalemia, administer calcium gluconate IV immediately, followed by therapies to shift potassium intracellularly, and then initiate measures to eliminate potassium from the body 4, 1, 2
The Mayo Clinic recommends using calcium gluconate 10%: 15-30 mL IV over 2-5 minutes, with alternative options including calcium chloride 10%: 5-10 mL IV over 2-5 minutes 1, 2
Continuous cardiac monitoring is necessary during and 5-10 minutes after administration, with repeat doses if no improvement in ECG is seen within 5-10 minutes 1

For moderate hyperkalemia without ECG changes, initiate intracellular shift therapies and potassium binders, reserving calcium for cases with electrocardiographic changes 1
The American Heart Association recommends using insulin 10 units regular IV + 25g dextrose, albuterol nebulized 10-20 mg in 4 mL, and bicarbonate only if metabolic acidosis is present 1

For mild hyperkalemia without ECG changes, focus on identifying and eliminating reversible causes, optimizing diuretic therapy, and considering potassium binders if the patient requires renin-angiotensin-aldosterone system (RAAS) inhibitors 1
The National Kidney Foundation recommends reviewing and eliminating contributing medications, optimizing diuretic therapy with loop or thiazide diuretics, and using potassium binders if necessary 1, 4

After acute resolution, reinstate RAAS inhibitors at lower doses once potassium <5.5 mEq/L with concurrent potassium binder therapy, as these medications provide mortality benefit in cardiovascular and renal disease 4, 1
The American College of Cardiology recommends verifying potassium levels within 1 week of initiating or escalating RAAS inhibitors, with reevaluation at 7-10 days after dose changes 4, 1

Patients with advanced chronic kidney disease (CKD) tolerate higher potassium levels due to compensatory mechanisms, with an optimal potassium range of 3.3-5.5 mEq/L for CKD stage 4-5 versus 3.5-5.0 mEq/L for stage 1-2 1
The National Kidney Foundation recommends maintaining a potassium target of 4.0-5.0 mEq/L to minimize mortality risk in patients with CKD 1